SICKLE CELL DISEASE IN JHABUA AND KHARGONE DISTRICT: UNVEILING PREVALENCE AND SEVERITY

RUCHI KUMARI; ANJALI KUSHWAH; AVINA KHARAT; NARLAPATI VIGNAN; SIDDHARTH OJHA; AKASH MISHRA; PAROMA SINHA

doi:10.22159/ijpps.2024v16i4.50497

Authors

RUCHI KUMARI Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India
ANJALI KUSHWAH Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India
AVINA KHARAT Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India
NARLAPATI VIGNAN Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India
SIDDHARTH OJHA Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India
AKASH MISHRA Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India
PAROMA SINHA Department of Pharmacology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, India

DOI:

https://doi.org/10.22159/ijpps.2024v16i4.50497

Keywords:

Sickle cell disease, Prevalence, Tribal population, Treatment pattern, Disease burden

Abstract

Objective: To assess the prevalence among Sickle cell disease (SCD) affected individuals emphasizing the neglected health challenges in various tribes.

Methods: Cross-sectional, observational study was conducted during the district residency program for 9 mo. The data has been collected from the record room of patients diagnosed with Sickle cell Anemia. Statistical analysis was done using Microsoft Excel.

Results: A total of 295 patients’ data revealed demographic skew toward Jhabua (50%), with Sickle cell anemia diagnosed at the mean age of 23±3.9. Most patients (72.3%) were Hindu, with Bhil and Bhilaya tribes having higher frequencies. Symptoms varied; 94% had Sickle cell trait, 16.3% had sickle cell disease, and 60% experienced painful crises. Treatment included prophylactic care for all, 37.57% required blood transfusions and 29.7% were on hydroxyurea.

Conclusion: The study underscores the significant SCD burden and the need for heightened awareness and targeted interventions in socio-economically disadvantaged tribal regions to mitigate the impact of SCD.

Downloads

Download data is not yet available.

References

Srikanthan S. Contested disability: sickle cell disease. Health Soc Work. 2023 Jul 21;48(3):209-16. doi: 10.1093/hsw/hlad014, PMID 37315205.

Narla A, Mohandas N. Screen ”play” for drug discovery. Proc Natl Acad Sci USA. 2022 Nov;119(45):e2215625119. doi: 10.1073/pnas.2215625119, PMID 36264843, PMCID PMC9659400.

Vidavalur R, Bhutani VK. Georacial epidemiological estimates of glucose-6-phosphate dehydrogenase deficiency among newborns in the United States. Am J Perinatol. 2023 May 31. doi: 10.1055/a-2082-4859, PMID 37105226.

Mangla A. Sickle cell anemia; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482164StatPearls-NCBIBookshelf. [Last accessed on 01 Mar 2024]

Office of the Registrar General & Census Commissioner. Ministry of Home Affairs, Govt of India. Census of India; 2011. Census of India. Available from: http://www.censusindia.gov.in. [Last accessed on 16 Nov 2023]

Singh U, Saxena PS, Bidwa AK, Singh M. Evaluation of microcytic hypochromic Anemiaby electrophoresis for hemoglobinopathies in young population. Asian J Pharm Clin Res. 2023;16(3):84-8. doi: 10.22159/ajpcr.2023v16i3.47370.

Dunlop KJ, Mozumder UK. The occurrence of sickle cell anaemia among a group of tea garden labourers in Upper Assam. Ind Med Gaz. 1952 Sep;87(9):387-91, PMID 13022091, PMCID PMC5191509.

Colah RB, Mukherjee MB, Martin S, Ghosh K. Sickle cell disease in tribal populations in India. Indian J Med Res. 2015 May;141(5):509-15. doi: 10.4103/0971-5916.159492, PMID 26139766, PMCID PMC4510747.

Ahmadi M, Beiranvand S, Poormansouri S, Matbouei M, Rohani C. Sense of coherence or self-efficacy as predictors of health-related quality of life in sickle cell disease patients. Ann Hematol. 2023 Mar;102(3):519-28. doi: 10.1007/s00277-022-05007-2, PMID 36331567, PMCID PMC9977875.

Jackson E, Karlson CW, Herring W, Okhomina VI, Lim CS, Morrow A. Prevalence of raised body mass index in paediatric sickle cell disease. J Paediatr Child Health. 2022 Oct;58(10):1829-35. doi: 10.1111/jpc.16118, PMID 35822947.

Colah RB, Mukherjee MB, Martin S, Ghosh K. Sickle cell disease in tribal populations in India. Indian J Med Res. 2015 May;141(5):509-15. doi: 10.4103/0971-5916.159492, PMID 26139766, PMCID PMC4510747.

Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013 Jan 12;381(9861):142-51. doi: 10.1016/S0140-6736(12)61229-X, PMID 23103089, PMCID PMC3547249.

Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010 Jan;85(1):6-13. doi: 10.1002/ajh.21550, PMID 19902523, PMCID PMC5046828.

Correction. Correction: Volume 342 Index (June 29, 2000). N Engl J Med. 2000;343(11):824. doi: 10.1056/NEJM200009143431123, PMID 10984574.

Praharsh KMR, Puthusserikkunnu BA, Selvara J, Jawahar N. Formulation and optimization of hydroxyurea loaded nanostructured lipid carriers using design of experiment for the effective treatment of ovarian cancer. International Journal of Applied Pharmaceutics. Available from: https://journals.innovareacademics.in/index.php/ijap/article/view/45464/26907.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13;387(10019):661-70. doi: 10.1016/S0140-6736(15)01041-7, PMID 26670617, PMCID PMC5724392.